Global Interventional Oncology Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Product;
Embolization Devices, Ablation Devices, and Support Devices.By Cancer Type;
Kidney, Lung, Breast, Liver, Bone Metastasis, and Others.By Procedure;
Thermal Ablation, Non-Thermal Ablation, Transcatheter Arterial Chemoembolization, Transcatheter Arterial Radioembolization, and Transcatheter Arterial Embolization.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Interventional Oncology Market (USD Million), 2021 - 2031
In the year 2024, the Global Interventional Oncology Market was valued at USD 2,830.20 million. The size of this market is expected to increase to USD 4,695.44 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.5%.
The Global Interventional Oncology Market encompasses a diverse array of medical devices and procedures designed to diagnose, treat, and manage various types of cancer through minimally invasive techniques. This market is experiencing significant growth driven by several factors, including technological advancements, increasing cancer incidence rates, and a shift towards less invasive treatment modalities.
Interventional oncology procedures involve the use of specialized devices such as ablation systems, embolization devices, and imaging technologies to precisely target and treat cancerous tumors. These procedures offer patients alternatives to traditional surgery, with benefits such as reduced recovery times, fewer complications, and improved quality of life.
One of the primary drivers of market growth is the rising incidence of cancer globally. As cancer rates continue to climb, there is a growing need for effective and less invasive treatment options that can be delivered with precision. Technological advancements in interventional oncology devices, such as improved imaging modalities and navigational systems, are enhancing the accuracy and safety of cancer treatments, further driving market expansion.
Geographically, North America and Europe currently dominate the interventional oncology market, owing to factors such as well-established healthcare infrastructure, high adoption rates of advanced medical technologies, and significant investment in cancer research and treatment. However, emerging markets in Asia-Pacific and Latin America are also experiencing rapid growth, fueled by expanding healthcare infrastructure, rising healthcare expenditure, and growing awareness about the benefits of minimally invasive cancer treatments.
The Global Interventional Oncology Market is poised for continued growth as technological innovation continues to drive the development of more advanced and effective devices, and as healthcare systems worldwide increasingly recognize the value of minimally invasive approaches in cancer care.
Global Interventional Oncology Market Recent Developments
-
In August 2022, Boston Scientific Corporation acquired Obsidio, Inc. This acquisition strengthens the company’s interventional oncology & embolization portfolio with the addition of Gel Embolic Material (GEM) technology, offering a differentiated solution to patients and physicians.
-
In July 2021, Terumo Europe announced the signing of a Memorandum of Understanding (MoU) with the University Medical Center Utrecht (UMC Utrecht) to extend their partnership and enhance education and innovations for the development of effective solutions in interventional oncology.
Segment Analysis
The market for cancer treatment devices is segmented based on product types, including embolization devices, ablation devices, and support devices. Embolization devices are used to block blood flow to tumors, while ablation devices are employed to destroy tumor tissues through various methods like heat, cold, or electrical currents. Support devices, on the other hand, play a critical role in assisting the main therapeutic devices during procedures. Each of these devices serves a specific function in treating various types of cancer, enhancing treatment effectiveness and patient outcomes.
The cancer treatment devices market is also divided by cancer type, including kidney, lung, breast, liver, bone metastasis, and others. Kidney cancer treatment often involves advanced techniques like embolization or thermal ablation to target the tumor. Lung and breast cancers, being among the most common, require a range of procedures, including ablation and embolization, tailored to the tumor's size and location. Liver cancer treatments focus heavily on embolization and chemoembolization methods due to the organ's blood flow characteristics. Bone metastasis treatments require specialized approaches, integrating multiple device types to address complex tumor growths.
Additionally, procedures in cancer treatments are segmented into thermal ablation, non-thermal ablation, transcatheter arterial chemoembolization (TACE), transcatheter arterial radioembolization (TARE), and transcatheter arterial embolization (TAE). Thermal ablation utilizes heat to destroy tumors, while non-thermal ablation involves methods like cryoablation or microwave therapy. TACE and TARE focus on targeting tumors through the blood vessels that supply them, delivering chemo or radiation agents directly. TAE is a less aggressive technique but still plays a crucial role in blocking tumor blood supply. Each of these procedures offers unique benefits depending on tumor type, location, and patient condition.
Global Interventional Oncology Segment Analysis
In this report, the Global Interventional Oncology Market has been segmented by Product, Cancer Type, Procedure and Geography.
Global Interventional Oncology Market, Segmentation by Product
In this report, the Global Interventional Oncology Market has been segmented by Product into Embolization Devices, Ablation Devices and Support Devices.
Embolization Devices play a crucial role in interventional oncology procedures by blocking or reducing blood flow to tumors, thereby depriving them of oxygen and nutrients essential for their growth. These devices include microspheres, coils, and particles, which are precisely delivered to the tumor site via catheters. Embolization procedures are commonly used to treat liver cancer, uterine fibroids, and other malignancies, offering patients a minimally invasive alternative to surgery. Ablation Devices represent another key segment within the interventional oncology market, encompassing technologies such as radiofrequency ablation (RFA), microwave ablation, and cryoablation. These devices deliver energy, either heat or extreme cold, to destroy cancerous tissue while sparing healthy surrounding tissue. Ablation procedures are effective for treating small to medium-sized tumors in various organs such as the liver, kidney, lung, and bone. They offer patients precise and targeted treatment options with reduced recovery times and fewer complications compared to traditional surgery.
Support Devices constitute the third segment, comprising a range of tools and accessories used to facilitate interventional oncology procedures. These devices include catheters, guidewires, imaging equipment, and drainage systems, among others. Support devices play a critical role in guiding interventional radiologists during procedures, ensuring accurate placement of embolization or ablation devices, and monitoring patient response in real-time. They enhance procedural efficacy, safety, and patient outcomes, contributing to the overall success of interventional oncology treatments. As the demand for minimally invasive cancer therapies continues to grow, driven by technological advancements and increasing adoption of interventional oncology procedures worldwide, the market for embolization, ablation, and support devices is expected to expand significantly in the coming years.
Global Interventional Oncology Market, Segmentation by Cancer Type
In this report, the Global Interventional Oncology Market has been segmented by Cancer Type into Kidney, Lung, Breast, Liver, Bone Metastasis and Others.
Kidney cancer stands as a significant segment within this market, covering interventions such as ablation and embolization techniques for renal cell carcinoma (RCC) and metastatic kidney tumors. These minimally invasive procedures offer patients precise treatment options with reduced recovery times and fewer complications compared to traditional surgery. Lung cancer represents another substantial segment, with interventions including ablation and embolization procedures for primary and metastatic lung tumors. These techniques provide viable treatment options for patients who are not suitable candidates for conventional surgery or chemotherapy. Additionally, breast cancer is a notable segment in the interventional oncology market, where procedures such as ablation and embolization are utilized for both primary and metastatic breast tumors. These minimally invasive approaches offer patients effective treatment options while minimizing the impact on surrounding healthy tissue and preserving breast function.
Liver cancer is another significant segment, encompassing interventions like ablation, embolization, and radioembolization for hepatocellular carcinoma (HCC) and metastatic liver tumors. These procedures offer targeted treatment options with the potential to improve patient outcomes and prolong survival. Furthermore, bone metastasis interventions are crucial in managing cancer that has spread to the bones, utilizing techniques such as ablation and embolization to alleviate pain and stabilize bone lesions. The "Others" category encompasses various other cancer types, including but not limited to gastrointestinal, gynecological, and prostate cancers. As the demand for minimally invasive cancer therapies continues to rise across different cancer types, driven by technological advancements and increasing awareness of their benefits, the market for interventional oncology devices tailored to these specific malignancies is expected to expand significantly in the coming years.
Global Interventional Oncology Market, Segmentation by Procedure
In this report, the Global Interventional Oncology Market has been segmented by Procedure into Thermal Ablation, Non-Thermal Ablation, Transcatheter Arterial Chemoembolization, Transcatheter Arterial Radioembolization and Transcatheter Arterial Embolization.
Thermal Ablation comprises procedures such as radiofrequency ablation (RFA), microwave ablation, and laser ablation, among others. These techniques involve the application of heat to destroy cancerous tissue while minimizing damage to surrounding healthy cells. Thermal ablation is commonly employed for treating tumors in various organs, offering patients a minimally invasive alternative to surgery with reduced recovery times and fewer complications. Non-Thermal Ablation encompasses procedures like cryoablation and irreversible electroporation (IRE), which utilize cold temperatures or electrical pulses to induce cell death in cancerous tissue. Cryoablation involves freezing cancer cells, while IRE disrupts cell membranes through the application of electrical fields. These non-thermal ablation techniques offer precise and targeted treatment options for tumors located near sensitive structures or in regions where thermal ablation may be challenging.
Transcatheter Arterial Chemoembolization (TACE) involves the delivery of chemotherapy drugs directly to the tumor site via catheter, followed by the embolization of blood vessels to restrict blood flow to the tumor. TACE is commonly used to treat liver cancer and hepatic metastases, offering a localized and targeted approach to chemotherapy delivery while minimizing systemic side effects. Transcatheter Arterial Radioembolization (TARE) or Selective Internal Radiation Therapy (SIRT) involves the delivery of radioactive microspheres directly into the blood vessels supplying the tumor. These microspheres emit radiation locally, targeting the tumor while sparing healthy surrounding tissue. TARE is primarily used for treating liver cancer and metastatic colorectal cancer, offering effective tumor control and symptom relief for patients who may not be candidates for surgery or other treatments. Transcatheter Arterial Embolization (TAE) or Bland Embolization involves the occlusion of blood vessels supplying the tumor using embolic agents such as microspheres, coils, or particles. TAE is often used as a palliative treatment to relieve symptoms and shrink tumors in patients with advanced cancer, providing symptomatic relief and improving quality of life. These various interventional oncology procedures offer clinicians a diverse toolkit for treating cancer patients with precision and efficacy, contributing to the overall growth of the interventional oncology market. As the demand for minimally invasive cancer therapies continues to rise, driven by technological advancements and increasing awareness of their benefits, the market for interventional oncology devices tailored to these procedures is expected to expand significantly in the coming years.
Global Interventional Oncology Market, Segmentation by Geography
In this report, the Global Interventional Oncology Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Interventional Oncology Market Share (%), by Geographical Region, 2024
North America remains a dominant market, driven by advanced healthcare infrastructure, high healthcare spending, and a growing prevalence of cancer. The U.S. is a key player in this region, with strong investments in research and development, alongside early adoption of new cancer treatment technologies. Europe, while also a significant market, is characterized by stringent regulatory requirements and varying healthcare systems across countries, which can influence the adoption and growth of cancer treatment devices.
In the Asia Pacific region, the market is expected to experience substantial growth due to the increasing prevalence of cancer and improving healthcare infrastructure. Countries like China, India, and Japan are witnessing advancements in medical technology, leading to greater access to cancer treatment devices. Additionally, a large patient population and rising healthcare expenditures are contributing to the demand for effective cancer therapies. The Middle East and Africa present a mixed market environment, with some regions benefiting from increasing investments in healthcare infrastructure, while others face challenges related to economic instability and healthcare access. Despite these challenges, there is a growing recognition of the need for advanced cancer treatment options in the region.
Latin America is another emerging market for cancer treatment devices, with increasing awareness of cancer prevention and treatment. Governments in countries like Brazil and Mexico are focusing on improving healthcare services and expanding access to cancer care, which in turn drives the demand for innovative treatment solutions. The report timeline from 2020 to 2030 indicates that while North America and Europe may continue to hold substantial market shares, regions like Asia Pacific and Latin America are likely to see the fastest growth due to economic development, rising healthcare investments, and the increasing burden of cancer in these areas.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Interventional Oncology Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunities
Drivers:
- Increasing Incidence of Cancer
- Technological Advancements
-
Growing Preference for Minimally Invasive Treatments:Minimally invasive procedures are gaining traction among patients and healthcare providers due to their array of benefits over traditional surgical approaches. These techniques, including radiofrequency ablation, microwave ablation, and transarterial chemoembolization, present less intrusive alternatives for tumor treatment. Patients appreciate the reduced hospital stays associated with these procedures, as well as the accelerated recovery times they offer. Moreover, the lower risk of complications compared to conventional surgery adds to their appeal, making them an attractive option for individuals seeking effective yet less invasive treatment options for cancer.
The rise in demand for minimally invasive interventions in oncology has notably contributed to the growth of the market. With advancements in interventional oncology techniques, such as improved targeting accuracy and enhanced efficacy in tumor treatment, these procedures are increasingly becoming the preferred choice for both patients and healthcare providers. As awareness spreads regarding the benefits of minimally invasive approaches and as technology continues to evolve, the market for interventional oncology is poised for further expansion, catering to the growing preference for procedures that prioritize patient comfort and outcomes.
Restraints:
- Limited Awareness and Accessibility
- High Cost of Treatment
-
Regulatory Challenges:Navigating the regulatory landscape for new interventional oncology devices and techniques often proves to be a formidable challenge for manufacturers. The intricate approval processes can be protracted and multifaceted, involving rigorous evaluations of safety, efficacy, and compliance with regulatory standards. These complexities contribute to delays in market entry and adoption, as companies must invest significant time and resources to satisfy regulatory requirements. Moreover, the stringent regulations imposed by regulatory authorities may escalate development costs for manufacturers, further impeding innovation in the field. The financial burden associated with achieving regulatory compliance, coupled with the prolonged timeframes for approval, may deter some companies from pursuing advancements in interventional oncology, stifling progress and limiting the availability of innovative technologies for patients and healthcare providers.
Despite the hurdles posed by regulatory challenges, there remains ample opportunity for collaboration and strategic engagement to streamline approval processes and foster innovation. By establishing partnerships between regulatory agencies, industry stakeholders, and research institutions, it becomes possible to address regulatory complexities more efficiently and expedite the approval of new interventional oncology devices and techniques. Additionally, advocacy efforts aimed at promoting greater transparency and predictability in regulatory frameworks can help alleviate some of the burdens faced by manufacturers, enabling them to focus on advancing novel solutions for cancer treatment. Ultimately, by fostering a collaborative environment that supports innovation while ensuring patient safety, regulatory challenges can be effectively navigated, paving the way for continued progress in interventional oncology.
Opportunities:
- Emerging Markets
- Personalized Medicine
-
Collaboration and Integration:Collaboration among interventional radiologists, oncologists, and various healthcare professionals is paramount for ensuring the delivery of comprehensive and holistic cancer care. By leveraging the expertise of each specialty, integrated care pathways can be developed to address the multifaceted needs of cancer patients effectively. Through such collaboration, interventional oncology can seamlessly complement other treatment modalities, such as surgery, chemotherapy, and radiation therapy, to provide patients with personalized and optimized treatment plans. This interdisciplinary approach allows for a more thorough assessment of patient conditions, enabling healthcare providers to tailor treatment strategies according to individual patient needs and preferences.
Integrated care pathways not only enhance treatment outcomes but also improve the overall patient experience throughout the cancer care journey. By coordinating care delivery across different specialties, healthcare professionals can minimize treatment redundancies, reduce the risk of adverse events, and streamline the care process for patients. Moreover, collaborative efforts foster a supportive and cohesive care environment where patients feel empowered and well-informed about their treatment options. As such, there are ample opportunities for partnerships and care coordination initiatives to further strengthen interdisciplinary collaboration in oncology care, ultimately leading to better patient outcomes and satisfaction.
Competitive Landscape Analysis
Key players in Global Interventional Oncology Market include
- Boston Scientific
- Terumo Corporation
- Medtronic
- BTG
- Ethicon
- AngioDynamics
- Merit Medical Systems
- Sirtex Medical
- Eckert & Ziegler
- BEBIG
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Product
- Market Snapshot, By Cancer Type
- Market Snapshot, By Procedure
- Market Snapshot, By Region
- Global Interventional Oncology Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Increasing Incidence of Cancer
- Technological Advancements
- Growing Preference for Minimally Invasive Treatments
- Restraints
- Limited Awareness and Accessibility
- High Cost of Treatment
- Regulatory Challenges
- Opportunties
- Emerging Markets
- Personalized Medicine
- Collaboration and Integration
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Interventional Oncology Market, By Product, 2021 - 2031 (USD Million)
- Embolization Devices
- Ablation Devices
- Support Devices
- Global Interventional Oncology Market, By Cancer Type, 2021 - 2031 (USD Million)
- Kidney
- Lung
- Breast
- Liver
- Bone Metastasis
- Others
- Global Interventional Oncology Market, By Procedure, 2021 - 2031 (USD Million)
- Thermal Ablation
- Non-Thermal Ablation
- Transcatheter Arterial Chemoembolization
- Transcatheter Arterial Radioembolization
- Transcatheter Arterial Embolization
- Global Interventional Oncology Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Interventional Oncology Market, By Product, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Boston Scientific
- Terumo Corporation
- Medtronic
- BTG
- Ethicon
- AngioDynamics
- Merit Medical Systems
- Sirtex Medical
- Eckert & Ziegler
- BEBIG
- Company Profiles
- Analyst Views
- Future Outlook of the Market